Andelyn Biosciences

Andelyn Biosciences is a pioneering gene therapy CDMO company born out of the viral vector core at Nationwide Children's Hospital. Our experts are globally recognized thought leaders with over 15 years of experience in AAV vector manufacturing. We have collaborated on more than 60 clinical trials in the U.S., EU, and ROW, and innovated Zolgensma – the first FDA-approved SMA gene therapy. We are your full-spectrum gene therapy partner, offering capabilities in viral vector process and analytical development, small to large-scale GMP production, fill/finish, and quality release testing. We also provide plasmid manufacturing services and vector development. Our state-of-the-art 200,000-square-foot commercial manufacturing facility will be operational in fall 2022, providing clinical to commercial-scale API and drug product manufacturing services. As an affiliate of Nationwide Children’s Hospital, Andelyn Biosciences' unique business model allows reinvestment into groundbreaking gene therapy research conducted by the world-class Abigail Wexner Research Institute to discover treatments for the next generation of rare diseases.